Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -2-
October 15, 2001
- Aiming at \300 Bil. Sales in FY2006: Mr Nagasaka of Banyu
October 15, 2001
- Taiho: Sales Up 3.9% to \96.4 Bil.
October 15, 2001
- Ribavirin, INF Combination Recommended for Approval for Hepatitis C
October 15, 2001
- Shionogi to Need 2 Years Before Obtaining Results of Restructuring
October 8, 2001
- Number of Diabetes Patients to Increase to 4.3 Mil. in 2010: Mr Nagae of Aventis
October 8, 2001
- BUSINESS NEWS IN BRIEF -1-
October 8, 2001
- BUSINESS NEWS IN BRIEF -2-
October 8, 2001
- Gastric Cancer Closely Linked with H. pylori Infection: Seminar
October 8, 2001
- Bill for Healthcare Reform to Be Presented to Diet Next Year -1-
October 8, 2001
- Losartan Shows Renal Protective Effects: NEJM
October 8, 2001
- WORLD NEWS IN BRIEF
October 8, 2001
- AIST, Toyo Shinyaku to Screen Plant Extracts That Kill Leukemia Cells
October 8, 2001
- Bill for Healthcare Reform to Be Presented to Diet Next Year -3-
October 8, 2001
- JPMA, ABPI Deepen R&D Exchanges
October 8, 2001
- Bill for Healthcare Reform to Be Presented to Diet Next Year -4-
October 8, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 8, 2001
- Dr Kurokawa Explains Background for Proposed PAL Amendment
October 8, 2001
- JMA, Hospital Associations Confirm Opposition to Operation of Hospitals by Private Companies
October 8, 2001
- REGULATORY NEWS IN BRIEF
October 8, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…